WO2002102997A3 - Isolated homozygous stem cells differentiated cells derived therefrom and materials and methods for making and using same - Google Patents

Isolated homozygous stem cells differentiated cells derived therefrom and materials and methods for making and using same Download PDF

Info

Publication number
WO2002102997A3
WO2002102997A3 PCT/US2001/044627 US0144627W WO02102997A3 WO 2002102997 A3 WO2002102997 A3 WO 2002102997A3 US 0144627 W US0144627 W US 0144627W WO 02102997 A3 WO02102997 A3 WO 02102997A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
methods
materials
making
same
Prior art date
Application number
PCT/US2001/044627
Other languages
French (fr)
Other versions
WO2002102997A2 (en
Inventor
Wen Liang Yan
Jingqi Lei
Hua Helen Lin
Ruchi Khanna
Steve Chien-Wen Huang
Minh-Thanh Nguyen
Original Assignee
Stemron Inc
Wen Liang Yan
Jingqi Lei
Hua Helen Lin
Ruchi Khanna
Steve Chien-Wen Huang
Minh-Thanh Nguyen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stemron Inc, Wen Liang Yan, Jingqi Lei, Hua Helen Lin, Ruchi Khanna, Steve Chien-Wen Huang, Minh-Thanh Nguyen filed Critical Stemron Inc
Priority to AU2001297880A priority Critical patent/AU2001297880B2/en
Priority to NZ526243A priority patent/NZ526243A/en
Priority to CA002430627A priority patent/CA2430627A1/en
Priority to KR10-2003-7007343A priority patent/KR20030088022A/en
Priority to IL15623401A priority patent/IL156234A0/en
Priority to EP01274145A priority patent/EP1395652A2/en
Priority to JP2003506451A priority patent/JP2004532648A/en
Publication of WO2002102997A2 publication Critical patent/WO2002102997A2/en
Publication of WO2002102997A3 publication Critical patent/WO2002102997A3/en
Priority to HK06100997.7A priority patent/HK1081225A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0608—Germ cells
    • C12N5/0611—Primordial germ cells, e.g. embryonic germ cells [EG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/04—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from germ cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/10—Conditioning of cells for in vitro fecondation or nuclear transfer

Abstract

The present invention discloses and describes pluripotent homozygous stem (HS) cells, and methods and materials for making same. The present invention also provides methods for differentiation of HS cells into progenitor (multipotent) cells or other desired ! cells, groups of cells or tissues. Further, the applications of the HS cells disclosed herein, include (but are not limited to) the diagnosis and treatment of various diseases (for example, genetic diseases, neurodegenerative diseases, endocrine-related disorders and cancer), traumatic injuries, cosmetic or therapeutic transplantation, gene therapy and cell replacement therapy.
PCT/US2001/044627 2000-11-30 2001-11-30 Isolated homozygous stem cells differentiated cells derived therefrom and materials and methods for making and using same WO2002102997A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU2001297880A AU2001297880B2 (en) 2000-11-30 2001-11-30 Isolated homozygous stem cells differentiated cells derived therefrom and materials and methods for making and using same
NZ526243A NZ526243A (en) 2000-11-30 2001-11-30 Isolated homozygous stem cells, differentiated cells derived therefrom, and materials and methods for making and using same
CA002430627A CA2430627A1 (en) 2000-11-30 2001-11-30 Isolated homozygous stem cells differentiated cells derived therefrom and materials and methods for making and using same
KR10-2003-7007343A KR20030088022A (en) 2000-11-30 2001-11-30 Isolated Homozygous Stem Cells Differentiated Cells Derived Therefrom and Materials and Methods for Making and Using Same
IL15623401A IL156234A0 (en) 2000-11-30 2001-11-30 Isolated homozygous stem cells, differentiated cells derived therefrom, and materials and methods for making and using same
EP01274145A EP1395652A2 (en) 2000-11-30 2001-11-30 Isolated homozygous stem cells differentiated cells derived therefrom and materials and methods for making and using same
JP2003506451A JP2004532648A (en) 2000-11-30 2001-11-30 Isolated homozygous stem cells, differentiated cells derived therefrom, and materials and methods for making and using the same
HK06100997.7A HK1081225A1 (en) 2000-11-30 2006-01-23 Isolated homozygous stem cells differentiated cells derived therefrom and materials and methods for making and using same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25394300P 2000-11-30 2000-11-30
US60/253,943 2000-11-30

Publications (2)

Publication Number Publication Date
WO2002102997A2 WO2002102997A2 (en) 2002-12-27
WO2002102997A3 true WO2002102997A3 (en) 2003-12-24

Family

ID=22962299

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/044627 WO2002102997A2 (en) 2000-11-30 2001-11-30 Isolated homozygous stem cells differentiated cells derived therefrom and materials and methods for making and using same

Country Status (12)

Country Link
US (1) US20020168763A1 (en)
EP (1) EP1395652A2 (en)
JP (2) JP2004532648A (en)
KR (2) KR20030088022A (en)
CN (1) CN100422315C (en)
AU (1) AU2001297880B2 (en)
CA (1) CA2430627A1 (en)
HK (1) HK1081225A1 (en)
IL (1) IL156234A0 (en)
NZ (1) NZ526243A (en)
RU (1) RU2322497C2 (en)
WO (1) WO2002102997A2 (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8273570B2 (en) * 2000-05-16 2012-09-25 Riken Process of inducing differentiation of embryonic cell to cell expressing neural surface marker using OP9 or PA6 cells
US7030292B2 (en) * 2001-01-02 2006-04-18 Stemron, Inc. Method for producing a population of homozygous stem cells having a pre-selected immunotype and/or genotype, cells suitable for transplant derived therefrom, and materials and methods using same
US7588937B2 (en) * 2001-10-03 2009-09-15 Wisconsin Alumni Research Foundation Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells
US8153424B2 (en) * 2001-10-03 2012-04-10 Wisconsin Alumni Research Foundation Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells
DE60233248D1 (en) * 2001-11-15 2009-09-17 Childrens Medical Center PROCESS FOR THE ISOLATION, EXPANSION AND DIFFERENTIATION OF FEDERAL STRAIN CELLS FROM CHORION ZOTTE, FRUIT WATER AND PLAZENTA AND THERAPEUTIC USES THEREOF
MXPA04007739A (en) 2002-02-12 2005-07-01 Raven Biotechnologies Inc Human fetal bladder-derived epithelial cells.
EP1513928B1 (en) * 2002-05-24 2019-08-21 Advanced Cell Technology, Inc. A bank of stem cells for producing cells for transplantation having hla antigens matching those of transplant recipients, and methods for making and using such a stem cell bank
US20040091936A1 (en) 2002-05-24 2004-05-13 Michael West Bank of stem cells for producing cells for transplantation having HLA antigens matching those of transplant recipients, and methods for making and using such a stem cell bank
CN100549163C (en) 2002-12-16 2009-10-14 技术研究及发展基金有限公司 The stem cell culture for preparing the method for no feeder cell, no allogenic human embryo stem cell and use this method preparation
US8790637B2 (en) 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
US8518390B2 (en) 2003-06-27 2013-08-27 Advanced Technologies And Regenerative Medicine, Llc Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells
CA2530533C (en) 2003-06-27 2015-02-10 Ethicon, Incorporated Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
US7875273B2 (en) 2004-12-23 2011-01-25 Ethicon, Incorporated Treatment of Parkinson's disease and related disorders using postpartum derived cells
US20060223177A1 (en) 2003-06-27 2006-10-05 Ethicon Inc. Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
US8491883B2 (en) 2003-06-27 2013-07-23 Advanced Technologies And Regenerative Medicine, Llc Treatment of amyotrophic lateral sclerosis using umbilical derived cells
US7875272B2 (en) 2003-06-27 2011-01-25 Ethicon, Incorporated Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells
KR20080109943A (en) * 2003-08-29 2008-12-17 위스콘신 얼럼나이 리서어치 화운데이션 Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells
CA2548910C (en) * 2003-12-11 2010-11-02 Japan Science And Technology Agency Method for three-dimensional cartilage tissue engineering using bone marrow cells in simulated microgravity environment
MX2009009225A (en) 2003-12-23 2009-09-28 Cythera Inc Definitive endoderm.
US8647873B2 (en) 2004-04-27 2014-02-11 Viacyte, Inc. PDX1 expressing endoderm
US7670596B2 (en) 2004-04-23 2010-03-02 Bioe, Inc. Multi-lineage progenitor cells
US7622108B2 (en) 2004-04-23 2009-11-24 Bioe, Inc. Multi-lineage progenitor cells
KR101278421B1 (en) * 2004-04-27 2013-07-15 비아싸이트, 인크. Pdx1 expressing endoderm
KR100644296B1 (en) * 2004-07-24 2006-11-10 정필훈 Bioengineering of the tooth and jaws via organ culture system
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
EP1962719A4 (en) 2005-08-29 2011-05-04 Technion Res And Dev Of Foundation Ltd Media for culturing stem cells
US20070128727A1 (en) * 2005-11-08 2007-06-07 Kraemer Fredric B Methods for differentiation of embryonic stem cells
US9175261B2 (en) 2005-12-16 2015-11-03 DePuy Synthes Products, Inc. Human umbilical cord tissue cells for inhibiting adverse immune response in histocompatibility-mismatched transplantation
JP5179376B2 (en) 2005-12-19 2013-04-10 エシコン・インコーポレイテッド In vitro growth of postpartum-extracted cells in roller bottles
US9125906B2 (en) 2005-12-28 2015-09-08 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
US9115342B2 (en) * 2006-01-31 2015-08-25 Daiichi Sankyo Company Method for purifying cardiomyocytes or programmed cardiomyocytes derived from stem cells or fetuses
EP2019858B1 (en) 2006-04-17 2012-06-13 BioE LLC Differentiation of multi-lineage progenitor cells to respiratory epithelial cells
JP5149791B2 (en) 2006-04-28 2013-02-20 第一三共株式会社 Method for inducing differentiation of cardiomyocytes from pluripotent stem cells
DK2733203T3 (en) 2006-08-02 2019-02-04 Technion Res & Dev Foundation PROCEDURES FOR EXPANSION OF EMBRYONAL STEM CELLS IN A SUSPENSION CULTURE
WO2008067142A2 (en) * 2006-11-08 2008-06-05 Wisconsin Alumni Research Foundation In vitro differentiation of hematopoietic cells from primate embryonic stem cells
JP5323845B2 (en) 2007-10-05 2013-10-23 エシコン・インコーポレイテッド Repair and reconstruction of kidney tissue using human umbilical cord tissue-derived cells
US8236538B2 (en) 2007-12-20 2012-08-07 Advanced Technologies And Regenerative Medicine, Llc Methods for sterilizing materials containing biologically active agents
GB0800524D0 (en) * 2008-01-14 2008-02-20 Univ Brighton Cell culture system
WO2010071864A1 (en) 2008-12-19 2010-06-24 Ethicon, Incorporated Treatment of lung and pulmonary diseases and disorders
US10179900B2 (en) 2008-12-19 2019-01-15 DePuy Synthes Products, Inc. Conditioned media and methods of making a conditioned media
BRPI1013409A2 (en) 2009-03-26 2018-01-16 Advanced Tech And Regenerative Medicine Llc human umbilical cord tissue cells as therapy for alzheimer's disease
US20100247495A1 (en) * 2009-03-30 2010-09-30 Tom Ichim Treatment of Muscular Dystrophy
WO2011058558A2 (en) 2009-11-12 2011-05-19 Technion Research & Development Foundation Ltd. Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state
JP2013531987A (en) * 2010-06-14 2013-08-15 キアゲン ゲーエムベーハー Method for determining a target cell or tissue for extracting biomolecules from a fixed biological sample
BR112014015424A2 (en) 2011-12-23 2018-05-22 Depuy Synthes Products Llc detection of cells derived from human umbilical cord tissue
PL2972193T3 (en) * 2013-03-13 2020-08-24 University Of Miami Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids
WO2016170938A1 (en) * 2015-04-20 2016-10-27 国立大学法人岡山大学 Non-human animal model of cancer and method for constructing same, cancer stem cell and method for producing same
CN107338214B (en) * 2016-04-29 2020-04-17 湖南光琇高新生命科技有限公司 Fibroblast, preparation method and application thereof, cell secretion and application thereof
US11085916B2 (en) * 2016-07-19 2021-08-10 Mandom Corporation Method for observing dynamics of sweat glands
KR102169122B1 (en) * 2016-12-29 2020-10-23 의료법인 성광의료재단 A method for manufacturing of mesenchymal stem cell
EA202190295A1 (en) * 2018-07-17 2021-06-11 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния T-cells with a chimeric antigenic receptor derived from pluripotent stem cells obtained by means of immunoengineering
CN109298174A (en) * 2018-09-26 2019-02-01 姜云瀚 A kind of multiple-color immunofluorescence labeling method and imaging method
CN113215081B (en) * 2021-06-01 2023-04-14 华中科技大学同济医学院附属同济医院 Method for inducing stem cells to differentiate into parathyroid cells and composition thereof

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993019166A1 (en) * 1992-03-23 1993-09-30 The University Of North Carolina At Chapel Hill Small animal model for studying cholesterol metabolism
WO1994024274A1 (en) * 1993-04-21 1994-10-27 The University Of Edinburgh Isolation, selection and propagation of animal transgenic stem cells
WO1997007668A1 (en) * 1995-08-31 1997-03-06 Roslin Institute (Edinburgh) Unactivated oocytes as cytoplast recipients for nuclear transfer
US5635386A (en) * 1989-06-15 1997-06-03 The Regents Of The University Of Michigan Methods for regulating the specific lineages of cells produced in a human hematopoietic cell culture
WO1999001163A1 (en) * 1997-07-03 1999-01-14 University Of Massachusetts Cloning using donor nuclei from non-serum starved, differentiated cells
WO1999055841A2 (en) * 1998-04-29 1999-11-04 University Of Edinburgh Process for obtaining stem cells
WO2001011011A2 (en) * 1999-08-05 2001-02-15 Mcl Llc Multipotent adult stem cells and methods for isolation
WO2001030978A1 (en) * 1999-10-28 2001-05-03 University Of Massachusetts Gynogenetic or androgenetic production of pluripotent cells and cell lines, and use thereof to produce differentiated cells and tissues
WO2001032015A1 (en) * 1999-11-02 2001-05-10 University Of Massachusetts, As Represented By Its Amherst Campus Use of haploid genomes for genetic diagnosis, modification and multiplication
WO2001059076A2 (en) * 2000-02-09 2001-08-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Premeiotic and postmeiotic origin of teratomas: isolated teratoma stem cells for therapeutic uses
WO2002031123A1 (en) * 2000-10-13 2002-04-18 The University Court Of The University Of Edinburgh Stem cells
WO2002034890A2 (en) * 2000-10-26 2002-05-02 University Of Edinburgh Pluripotential stem cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843780A (en) * 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5905042A (en) * 1996-04-01 1999-05-18 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Cultured inner cell mass cell lines derived from bovine or porcine embryos
US5945577A (en) * 1997-01-10 1999-08-31 University Of Massachusetts As Represented By Its Amherst Campus Cloning using donor nuclei from proliferating somatic cells
AU5575899A (en) * 1998-08-20 2000-03-14 Biotransplant Incorporated Inbred mhc-homozygous miniature swine and uses thereof
US20030027331A1 (en) * 2000-11-30 2003-02-06 Yan Wen Liang Isolated homozygous stem cells, differentiated cells derived therefrom, and materials and methods for making and using same
US7030292B2 (en) * 2001-01-02 2006-04-18 Stemron, Inc. Method for producing a population of homozygous stem cells having a pre-selected immunotype and/or genotype, cells suitable for transplant derived therefrom, and materials and methods using same

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635386A (en) * 1989-06-15 1997-06-03 The Regents Of The University Of Michigan Methods for regulating the specific lineages of cells produced in a human hematopoietic cell culture
WO1993019166A1 (en) * 1992-03-23 1993-09-30 The University Of North Carolina At Chapel Hill Small animal model for studying cholesterol metabolism
WO1994024274A1 (en) * 1993-04-21 1994-10-27 The University Of Edinburgh Isolation, selection and propagation of animal transgenic stem cells
WO1997007668A1 (en) * 1995-08-31 1997-03-06 Roslin Institute (Edinburgh) Unactivated oocytes as cytoplast recipients for nuclear transfer
WO1999001163A1 (en) * 1997-07-03 1999-01-14 University Of Massachusetts Cloning using donor nuclei from non-serum starved, differentiated cells
WO1999055841A2 (en) * 1998-04-29 1999-11-04 University Of Edinburgh Process for obtaining stem cells
WO2001011011A2 (en) * 1999-08-05 2001-02-15 Mcl Llc Multipotent adult stem cells and methods for isolation
WO2001030978A1 (en) * 1999-10-28 2001-05-03 University Of Massachusetts Gynogenetic or androgenetic production of pluripotent cells and cell lines, and use thereof to produce differentiated cells and tissues
WO2001032015A1 (en) * 1999-11-02 2001-05-10 University Of Massachusetts, As Represented By Its Amherst Campus Use of haploid genomes for genetic diagnosis, modification and multiplication
WO2001059076A2 (en) * 2000-02-09 2001-08-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Premeiotic and postmeiotic origin of teratomas: isolated teratoma stem cells for therapeutic uses
WO2002031123A1 (en) * 2000-10-13 2002-04-18 The University Court Of The University Of Edinburgh Stem cells
WO2002034890A2 (en) * 2000-10-26 2002-05-02 University Of Edinburgh Pluripotential stem cells

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
HENERY C C ET AL: "CLEAVAGE RATE OF HAPLOID AND DIPLOID PARTHENOGENETIC MOUSE EMBRYOS DURING THE PREIMPLANTATION PERIOD", MOLECULAR REPRODUCTION AND DEVELOPMENT, LISSS, NEW YORK, NY, US, vol. 31, no. 4, April 1992 (1992-04-01), pages 258 - 263, XP001119277, ISSN: 1040-452X *
KAUFMAN M H ET AL: "ESTABLISHMENT OF PLURIPOTENTIAL CELL LINES FROM HAPLOID MOUSE EMBRYOS", JOURNAL OF EMBRYOLOGY AND EXPERIMENTAL MORPHOLOGY, COMPANY OF BIOLOGIST LTD., CAMBRIDGE, GB, vol. 73, 1 February 1983 (1983-02-01), pages 249 - 261, XP000569942, ISSN: 0022-0752 *
KEENE C D ET AL: "Transplantation of bone marrow-derived multipotent adult stem cells into the rat CNS: phenotypic expression.", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 26, no. 1-2, 2000, 30th Annual Meeting of the Society of Neuroscience;New Orleans, LA, USA; November 04-09, 2000, pages Abstract No. - 327.6, XP001145896, ISSN: 0190-5295 *
KONO T ET AL: "DEVELOPMENT OF ANDOGENETIC MOUSE EMBRYOS PRODUCED BY IN VITRO FERTILIZATION OF ENUCLEATED OOCYTES", MOLECULAR REPRODUCTION AND DEVELOPMENT, LISSS, NEW YORK, NY, US, vol. 34, 1993, pages 43 - 46, XP002938438, ISSN: 1040-452X *
MODLINSKI J A: "HAPLOID MOUSE EMBRYOS OBTAINED BY MICROSURGICAL REMOVAL OF ONE PRONUCLEUS", JOURNAL OF EMBRYOLOGY AND EXPERIMENTAL MORPHOLOGY, COMPANY OF BIOLOGIST LTD., CAMBRIDGE, GB, vol. 33, no. 4, 1975, pages 897 - 905, XP002939040, ISSN: 0022-0752 *
PERA M F ET AL: "ISOLATION AND CHARACTERIZATION OF A MULTIPOTENT CLONE OF HUMAN EMBRYONAL CARCINOMA CELLS", DIFFERENTIATION, SPRINGER VERLAG, DE, vol. 42, no. 1, 1989, pages 10 - 23, XP001015217, ISSN: 0301-4681 *
QI HUILIN ET AL: "Identification of genes responsible for bone differentiation from human bone marrow derived multipotent adult stem cells (MASC).", BLOOD, vol. 96, no. 11 Part 1, 16 November 2000 (2000-11-16), 42nd Annual Meeting of the American Society of Hematology;San Francisco, California, USA; December 01-05, 2000, pages 70a - 71a, XP002955582, ISSN: 0006-4971 *
SUTTER DE P ET AL: "CYTOGENETIC ANALYSIS OF HUMAN OOCYTES PARTHENOGENETICALLY ACTIVATED BY PUROMYCIN", JOURNAL OF ASSISTED REPRODUCTION AND GENETICS, PLENUM PUBLISHING, US, vol. 11, no. 8, September 1994 (1994-09-01), pages 382 - 388, XP001119476, ISSN: 1058-0468 *
TAYLOR A S ET AL: "THE EARLY DEVELOPMENT AND DNA CONTENT OF ACTIVATED HUMAN OOCYTES AND PARTHENOGENETIC HUMAN EMBRYOS", HUMAN REPRODUCTION, IRL PRESS, OXFORD, GB, vol. 9, no. 12, December 1994 (1994-12-01), pages 2389 - 2397, XP001118663, ISSN: 0268-1161 *
WINSTON N ET AL: "PARTHENOGENETIC ACTIVATION AND DEVELOPMENT OF FRESH AND AGED HUMAN OOCYTES", FERTILITY AND STERILITY, vol. 56, no. 5, 1991, pages 904 - 912, XP009007659, ISSN: 0015-0282 *

Also Published As

Publication number Publication date
US20020168763A1 (en) 2002-11-14
KR20030088022A (en) 2003-11-15
AU2001297880B2 (en) 2007-05-31
CA2430627A1 (en) 2002-12-27
RU2003119168A (en) 2005-02-20
KR20080051191A (en) 2008-06-10
WO2002102997A2 (en) 2002-12-27
HK1081225A1 (en) 2006-05-12
CN1643135A (en) 2005-07-20
RU2322497C2 (en) 2008-04-20
EP1395652A2 (en) 2004-03-10
JP2004532648A (en) 2004-10-28
JP2009028049A (en) 2009-02-12
NZ526243A (en) 2006-02-24
CN100422315C (en) 2008-10-01
AU2001297880B8 (en) 2003-01-02
IL156234A0 (en) 2004-01-04

Similar Documents

Publication Publication Date Title
WO2002102997A3 (en) Isolated homozygous stem cells differentiated cells derived therefrom and materials and methods for making and using same
WO2004003182A3 (en) Homozygous stem cells isolated from pathogenic oocytes
WO1999046366A8 (en) Uses for humane non-autologous mesenchymal stem cells
WO2000073421A3 (en) Methods of isolation, cryopreservation, and therapeutic use of human amniotic epithelial cells
WO2005095450A3 (en) Therapeutic use of a growth factor, nsg33
WO2002064748A8 (en) Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
WO2003066072A3 (en) Cell therapy using immunoregulatory t-cells
WO2003040346A3 (en) Methods and compositions for the use of stromal cells to support embryonic and adult stem cells
WO1999006548A3 (en) 5'ESTs FOR NON TISSUE SPECIFIC SECRETED PROTEINS
WO2004013310A3 (en) Methods of down regulating target gene expression in vivo by introduction of interfering rna
WO2000006705A3 (en) Genetically modified cd34-negative adherently growing stem cells and their use in gene therapy
WO2004010959A3 (en) Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith
WO1998019167A3 (en) Cell stress regulated human mhc class i gene
WO1999006549A3 (en) 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN TESTIS AND OTHER TISSUES
ATE361933T1 (en) 5' ESTS FOR SECRETED PROTEINS FROM BRAIN TISSUE
WO2001070977A3 (en) Fibroblast growth factor receptor-like molecules and uses thereof
WO2002007749A3 (en) Device providing regulated growth factor delivery for the regeneration of peripheral nerves
WO1999006553A3 (en) 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN VARIOUS TISSUES
WO2002028906A3 (en) Regulation of human sphingosine kinase-like protein
NZ504445A (en) Nucleic acid sequences of genes of the high mobility group proteins and their use in treating tumours, vascular disorders and as a contraceptive
WO2005047469A3 (en) PORCINE ISOGLOBOSIDE 3 SYNTHASE PROTEIN, cDNA, GENOMIC ORGANIZATION, AND REGULATORY REGION
WO2003025151A3 (en) Circadian control of stem/progenitor cell self-renewal and differentiation and of clock controlled gene expression
WO2001031008A3 (en) Human and rat fgf-20 genes and gene expression products
MXPA02000680A (en) Vgf polypeptides and methods of treating vgf-related disorders.
WO2001094586A3 (en) Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2430627

Country of ref document: CA

Ref document number: 2003506451

Country of ref document: JP

Ref document number: 1020037007343

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 156234

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 526243

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2001297880

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001274145

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 018223958

Country of ref document: CN

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020037007343

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001274145

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 526243

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2001297880

Country of ref document: AU